Engineered virus primes immune attack against glioblastoma
TL;DR
A phase 1 trial in 41 patients with recurrent glioblastoma found that a single injection of a modified herpes simplex virus can kill tumor cells and recruit enduring T cell activity into the tumor, correlating with longer survival than historical outcomes.
Topics:healthhealth-and-medicine#brain-cancer#glioblastoma#health-and-medicine#immunotherapy#oncolytic-virus#t-cells
Want the full story? Read the original reporting
Read on ScienceDaily